Royalty Pharma Plc (RPRX)
Royalty Pharma Plc (RPRX) carries a ŷRobot AI score of 73 out of 100. The model's fair value estimate is $62.03, 5.2% above the last close of $58.99. The chart signal reads Bearish.
| Metric | RPRX |
|---|---|
| AI score | 73 / 100 |
| Chart signal | Bearish |
| Fair value estimate | $62.03 |
| Upside to fair value | 5.2% |
| Previous close | $58.99 |
| P/E | 31.38 |
| Price / sales | 10.25 |
| Market cap | $32.69B |
| EPS | 1.86 |
| Revenue growth | 1.4% |
| 1-year price change | 12.7% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about RPRX
Is RPRX overvalued or undervalued right now?
As of Oct 14, 2026, ŷRobot's fair-value model estimates Royalty Pharma Plc (RPRX) at $62.03 against a last close of $58.99, implying 5.2% upside to the model's estimate.
Is RPRX's chart signal bullish or bearish?
The chart-signal model classifies RPRX as Neutral as of Oct 14, 2026, with a signal score of -0.01 on a -1 to 1 scale.
What is RPRX's ŷRobot AI score?
RPRX scores 73 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Oct 14, 2026.
Is RPRX stock expensive on P/E and P/S?
RPRX trades at 31.4 times earnings and 10.2 times sales as of Oct 14, 2026.
What does RPRX's seasonal forecast show?
ŷRobot's seasonal forecast curve for RPRX reads +2.3% at 30 days, +6.1% at 90 days, and +12.7% at one year as of Oct 14, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is RPRX growing?
Royalty Pharma Plc's revenue growth is +1.4% and free-cash-flow growth is +2.1% on the latest reported figures.
RPRX chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.